Modelos europeos de telemedicina, como el servicio finlandés Medilux, permiten realizar consultas médicas online mediante un cuestionario clínico, sin acudir a una consulta presencial.

In-stent CTO: different prognosis from that of De Novo CTO?

Courtesy of Dr. Carlos Fava.

In-stent CTO: Different Prognosis from that of De Novo CTO?Chronic Total Occlusions (CTO) are truly challenging and different technologies are being developed to treat them, but currently our most pressing questions about them are whether in-stent CTO present the same success rate as de novo CTO, and what their prognosis is.

 

The present trial analyzed 899 CTO: 111(12.3%) were in-stent CTO and (IS-CTO) and 788 de novo CTO.

 

Both cohorts had similar characteristics, except for higher rates of AMI and PCI in the IS-CTO group.

 

There were no differences in angiographic characteristics, treated vessel, J-CTO (1.88±1.24) or PROGRESS-CTO scores (1.04±0.88). The IS-CTO cohort presented lower moderate/severe calcification and bifurcation distal to occlusion, more often >20 mm occlusion, and less adequate area for stent implantation.

 

There was a lower tendency to use the transradial approach in IS-CTO. Antegrade wire escalation was more frequent (59.0% of IS-CTO and 48.1% of de novo CTO p=0.08). The retrograde, dissection and re-entry techniques were less frequent in de novo CTO.

 

Second generation DES were preferred in both cohorts. Technical success was 87%, and procedural success, 86%.

 

90% of patients were followed up at 471 days (354-872). MACE was superior in the IS-CTO group (20.8% vs. 13.9% p=0.07), mainly driven by TVR (16.7% vs. 9.4% p=0.03), with no difference in death or MI related to the treated vessel.

IS-CTO was an independent predictor of MACE, with >2 fold increase at follow up.

 

Conclusion

Procedural success in IS-CTO was high and had similar results to those of de novo CTO. However, IS-CTO was independently associated with higher MACE driven by TVL at follow up.

 

Comment

It is worth noting that, in a program with a high number of CTO cases, more than 10% are in-stent CTO, which, compared to de novo CTO, have higher MACE rate at the expense of higher ischemia driven TLR.

 

In addition, IS-CTO required more use of crossing devices (this study used CrossBoss), which certainly increased costs.

 

We should bear in mind that, even though cohorts were similar, IS-CTO cohort presented more prior AMI and PCI. These data may negatively affect long term prognosis.

 

Courtesy of Dr. Carlos Fava.

 

Original Title: Procedural and long-Term Outcomes of Percutaneous Coronary Intervention for In-Stent Chronic Total Occlusion.

Reference: Lorenzo Azzalini, et al. J Am Coll Cardiol Intv 2017; 10:892-902.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

EuroPCR 2026 | 10-Year Left Main PCI: When Survival Is Similar, Should the Less Invasive Strategy Prevail?

The primary goal of revascularization in left main coronary artery disease (LMCA) is to improve survival. However, debate continues regarding whether, in anatomically suitable...

EuroPCR 2026 | TAVI and Coronary Artery Disease: FFR-Guided PCI Showed Better Outcomes Than an Angiography-Guided Strategy

In patients undergoing TAVI, the concomitant presence of coronary artery disease continues to generate debate: whether coronary lesions should be treated before, during, or...

EuroPCR 2026 | Evolocumab Reduces Cardiovascular Events in Patients With Prior PCI Without Previous Myocardial Infarction: VESALIUS-CV Results

This presentation, delivered by Dr. Brian A. Bergmark and colleagues at EuroPCR 2026, detailed the results of the VESALIUS-CV trial, focusing specifically on the...

EuroPCR 2026 | Is It Safe to Stop Aspirin After One Month in MI Patients Undergoing PCI? TARGET-FIRST Analysis

This is a summary of the post-hoc analysis of the TARGET-FIRST study, presented by Dr. Giuseppe Tarantini at EuroPCR 2026, evaluating early aspirin discontinuation...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

EuroPCR 2026 | MELA Registry: Myval Showed Lower Aortic Regurgitation Rates in Patients With Large Aortic Annuli

This presentation, delivered by Dr. Salvatore Giordano at EuroPCR 2026, detailed the results of the MELA Registry, a multicenter study comparing the performance of...

EuroPCR 2026 | LANDMARK Trial: Two-Year Results Showed Comparable Efficacy Between Myval and Contemporary TAVI Valves

The LANDMARK trial presentation, delivered by Prof. Patrick W. Serruys at EuroPCR 2026, detailed the two-year clinical outcomes of contemporary transcatheter aortic valve implantation...

EuroPCR 2026 | 10-Year Left Main PCI: When Survival Is Similar, Should the Less Invasive Strategy Prevail?

The primary goal of revascularization in left main coronary artery disease (LMCA) is to improve survival. However, debate continues regarding whether, in anatomically suitable...